Top 10 GLP-1 Weight Loss Medications Transforming Health in 2026

Wegovy is Novo Nordisk's brand name for semaglutide 2.4 mg delivered as a once-weekly subcutaneous injection, approved by the FDA in June 2021 for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. It is a pure GLP-1 receptor agonist — semaglutide binds to and activates the GLP-1 receptor with very high potency and, critically, has a long half-life of approximately one week, allowing for once-weekly dosing. The higher 2.4 mg dose used in Wegovy (versus the 1 mg or 2 mg doses in Ozempic) was specifically engineered to maximize weight-loss efficacy. The STEP 1 Phase 3 trial in adults without diabetes demonstrated average weight loss of 14.9% at 68 weeks — roughly 34 pounds — versus 2.4% for placebo. Among completers who adhered to treatment, average weight loss approached 16-17%. Importantly, Wegovy has a landmark cardiovascular outcomes dataset that no other pure weight-loss drug can match: the SELECT trial enrolled 17,604 non-diabetic adults with obesity or overweight and established cardiovascular disease (CVD), and demonstrated a 20% relative risk reduction in major adverse cardiovascular events (MACE) — heart attack, stroke, or cardiovascular death — over an average of 34 months. This led to FDA approval of a cardiovascular risk-reduction indication in March 2024, making Wegovy the first weight-loss drug ever approved to protect the heart. Weekly doses escalate from 0.25 mg through 0.5, 1.0, 1.7, and ultimately 2.4 mg over 16-20 weeks to minimize gastrointestinal side effects. Wegovy is delivered via a pre-filled, single-use autoinjector pen. The drug faces supply constraints that have historically limited access, though manufacturing expansion has improved availability. Monthly list price is approximately $1,349, with Novo Nordisk's savings program bringing costs to as low as $25 per month for eligible commercially insured patients.

Retatrutide is Eli Lilly's investigational triple receptor agonist, simultaneously activating GLP-1, GIP, and glucagon receptors — a pharmacological combination with no approved precedent. By adding glucagon receptor agonism to the dual GIP/GLP-1 profile of tirzepatide, retatrutide targets a third metabolic axis: energy expenditure. Glucagon receptor activation increases thermogenesis and fat oxidation in the liver and adipose tissue, providing a mechanism for weight loss that goes beyond appetite suppression alone. The Phase 2 trial published in 2023 showed up to 24% weight loss at 48 weeks in adults without diabetes at the 12 mg weekly dose — results that electrified the obesity medicine field. Then the Phase 3 program delivered results that were even more remarkable. TRIUMPH-4, reported in December 2025, showed a mean body-weight reduction of 28.7% at 68 weeks in the 12 mg group. Most strikingly, TRIUMPH-1, the pivotal obesity trial with its topline data announced in May 2026, reported up to 30.3% average weight loss at the highest dose — the single greatest weight-loss result ever recorded in a randomized Phase 3 clinical trial. At 12 mg over 96 weeks, participants had lost an average of approximately 70-71 pounds. Additional TRIUMPH-4 findings included a 75.8% reduction in osteoarthritis pain scores, approximately 20% reduction in LDL cholesterol, and a 72% reversal rate of prediabetes to normoglycemia. An NDA filing with the FDA is anticipated in late 2026, with approval expected in late 2027. Seven additional Phase 3 trials are reporting throughout 2026 across obesity subtypes, type 2 diabetes, and cardiovascular disease. Retatrutide does not yet have a commercial brand name, a list price, or an approved indication — but given the Phase 3 data, it represents the most anticipated drug in obesity medicine since Wegovy's 2021 approval.

CagriSema is Novo Nordisk's investigational fixed-dose combination of cagrilintide 2.4 mg (a long-acting amylin analogue) and semaglutide 2.4 mg, delivered as a single once-weekly subcutaneous injection. It represents a novel dual-hormone approach to weight management that goes beyond the GLP-1 receptor alone by adding amylin receptor activation. Amylin is a peptide hormone co-secreted with insulin from pancreatic beta cells, and it plays complementary roles in appetite suppression: it slows gastric emptying, suppresses glucagon secretion, and produces satiety signals via the central nervous system, particularly the area postrema and hypothalamus — pathways that are partially distinct from GLP-1 signaling. The hypothesis underlying CagriSema is that dual-pathway engagement produces additive or synergistic weight loss beyond what semaglutide achieves alone. The REDEFINE 1 Phase 3 trial in adults with obesity or overweight (without type 2 diabetes) reported impressive results: among participants evaluated for the treatment effect if all patients stayed on treatment, average weight loss was 22.7% at approximately 68 weeks. The full population analysis showed 20% average weight loss. Crucially, 91.9% of CagriSema-treated participants achieved at least 5% weight reduction, compared to 31.5% with placebo. Approximately one-third of participants reached 25% or greater weight loss, approaching surgical outcomes. Novo Nordisk submitted an NDA to the FDA on December 18, 2025, making CagriSema the most advanced next-generation obesity drug in the regulatory pipeline. The FDA is expected to complete its review in 2026, with a potential approval decision by late 2026 or early 2027. CagriSema is not yet approved in the US or EU. If approved, it would be the first amylin-class drug approved for obesity, representing a new mechanistic pillar in the field.

The oral Wegovy pill — formally oral semaglutide 25 mg — represents one of the most significant pharmaceutical advances in obesity medicine in years: it delivers the same active molecule as the injectable Wegovy in a once-daily tablet, eliminating the barrier of self-injection for patients who fear needles or prefer pill-based therapy. Approved by the FDA on December 22, 2025, and commercially available from January 2026, it is the first oral GLP-1 receptor agonist approved specifically for weight management in adults with obesity or overweight with at least one comorbidity. The OASIS 4 Phase 3 trial demonstrated that oral semaglutide 25 mg, taken once daily alongside a reduced-calorie diet and increased physical activity, produced an average weight loss of 16.6% among adherent participants — essentially matching the efficacy of injectable Wegovy in those who remained on treatment. The full population analysis (including those who discontinued) showed approximately 14% average weight loss. One-third of adherent participants achieved 20% or greater weight loss, compared to under 3% with placebo. Oral semaglutide does have one notable compliance requirement: the tablet must be taken on an empty stomach (fasting for at least 6 hours), with no more than 120 mL (4 oz) of plain water, and no food or drink for at least 30 minutes after ingestion. This is because GLP-1 peptides are poorly absorbed when co-ingested with food, and the tablet uses a proprietary absorption enhancer (SNAC — sodium N-[8-(2-hydroxybenzoyl)aminocaprylate]) to protect semaglutide from gastric digestion. This dosing protocol is stricter than the competitor oral GLP-1, Foundayo (orforglipron), which can be taken at any time without food restrictions — a practical distinction worth noting for patients with busy morning routines. List price is set at approximately $499 per month, with Novo Nordisk expected to offer savings programs. The oral formulation also carries the cardiovascular risk-reduction indication in adults with established CVD that was approved alongside the weight-loss NDA.

Foundayo (orforglipron) is Eli Lilly's FDA-approved once-daily oral GLP-1 receptor agonist approved on April 1, 2026 — a landmark drug for a specific reason beyond its efficacy. Unlike the oral semaglutide pill (Wegovy oral, Rybelsus), orforglipron is a small-molecule, non-peptide GLP-1 receptor agonist. This chemical class distinction has a critical practical consequence: because it is not a peptide, it does not get degraded by digestive enzymes in the way that semaglutide does, and it does not require a complex absorption enhancer. As a result, Foundayo can be taken at any time of day, with or without food, and without water restrictions — a unique advantage over all other oral GLP-1 drugs currently approved. The Phase 3 ATTAIN clinical trial program evaluated orforglipron across multiple doses and populations. At the highest dose (36 mg once daily) over 72 weeks, participants achieved an average weight loss of 12.4% — approximately 27 pounds — with an estimated 60% of participants achieving at least 10% body weight reduction. While 12.4% is lower than the 16.6% achieved with oral semaglutide in OASIS 4, the no-food-restriction dosing protocol may make adherence meaningfully better in real-world settings, particularly for patients with demanding work schedules or irregular meal patterns. Orforglipron launched commercially on April 6, 2026, via LillyDirect, followed by broader pharmacy and telehealth distribution. Critically, Lilly priced it at $149 per month for self-pay patients — dramatically below every other GLP-1 on the market. Some commercially insured patients pay as little as $25 per month with Lilly's savings card. This pricing strategy represents a deliberate effort to expand GLP-1 access well beyond the well-insured populations that have predominantly used Wegovy and Zepbound. Orforglipron does not yet carry a cardiovascular indication; outcomes trials are underway.

Ozempic contains the same molecule as Wegovy — semaglutide — but is FDA-approved primarily for glycemic control in type 2 diabetes at doses up to 2 mg weekly, and has accumulated the most expansive indication label of any GLP-1 receptor agonist on the market. Approved initially in December 2017, Ozempic now holds three distinct FDA-approved indications: (1) glycemic control in adults with type 2 diabetes; (2) reduction of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease (based on the SUSTAIN-6 and SELECT-adjacent data); and (3) — its most recent and clinically significant expansion, approved January 28, 2025 — reduction of the risk of worsening kidney disease, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease (CKD), based on the Phase 3b FLOW trial. The FLOW kidney outcomes trial is one of the most consequential studies in nephrology in decades. It demonstrated a 24% relative risk reduction in the composite of kidney disease worsening, end-stage kidney disease, and cardiovascular death with semaglutide versus placebo in a high-risk population with CKD (eGFR 25-75 mL/min/1.73m2). Additionally, it showed a 29% relative risk reduction in cardiovascular death — establishing semaglutide as the only GLP-1 RA approved to protect kidneys. While Ozempic is not formally approved for weight management (that indication sits with Wegovy at 2.4 mg), its use produces meaningful weight reduction as a beneficial secondary effect — typically 5-10% at the 1-2 mg doses — and it is one of the most commonly prescribed GLP-1s globally. Monthly list price is approximately $900-$1,000 without insurance; diabetes indications give it better insurance coverage than Wegovy in many plans. As the diabetes-labeled version of semaglutide, Ozempic serves as the entry point into the semaglutide family for millions of patients globally.

MariTide (maridebart cafraglutide) is Amgen's investigational antibody-peptide conjugate for obesity that targets the GLP-1 receptor as an agonist while simultaneously antagonizing the GIP receptor — a mechanistic approach that is the inverse of tirzepatide, which agonizes both GIP and GLP-1. The rationale is that blocking GIP signaling, rather than activating it, may reduce the energy-storing properties of GIP in adipose tissue while still benefiting from GLP-1-mediated appetite suppression. This hypothesis is pharmacologically contested — tirzepatide's GIP agonism clearly works — but MariTide's Phase 2 data demonstrate that GIP antagonism combined with GLP-1 agonism also produces meaningful weight loss. The Phase 2 trial results, published in the New England Journal of Medicine and presented at the American Diabetes Association's 85th Scientific Sessions, showed up to approximately 20% weight loss in non-diabetic adults with obesity after 52 weeks. Among participants with type 2 diabetes, weight loss reached approximately 17%, with HbA1c reductions of up to 1.6 percentage points and a high percentage achieving normoglycemia. Crucially, MariTide also demonstrated sustained weight loss for up to 52 weeks after the treatment period ended in some dose groups — a potential durability advantage over peptide-based GLP-1s, whose effects wane quickly after discontinuation. MariTide's most structurally distinctive feature is its dosing frequency: it is being developed as a once-monthly injection, and potentially even a once-quarterly formulation in the longer term, versus weekly injections for all current GLP-1s. This represents a paradigm-shifting convenience advantage if confirmed in Phase 3. However, Phase 2 results disappointed Wall Street relative to pre-release expectations (as reported by BioPharma Dive), and Phase 3 data will be decisive. Phase 3 studies are underway and will read out over 2026-2027.

Rybelsus is Novo Nordisk's once-daily oral semaglutide tablet approved in September 2019 for glycemic control in adults with type 2 diabetes. It was the world's first oral GLP-1 receptor agonist — a significant pharmaceutical achievement, given that GLP-1 peptides are ordinarily destroyed by gastric acid and proteases when taken by mouth. Rybelsus uses the proprietary SNAC (sodium N-[8-(2-hydroxybenzoyl)aminocaprylate]) absorption enhancer technology, which transiently raises local gastric pH and facilitates semaglutide absorption across the gastric mucosa. The mechanism requires strict fasting conditions: Rybelsus must be taken on an empty stomach with no more than 120 mL of plain water, with no food, drink, or other medications for at least 30 minutes afterward. Available in 3 mg, 7 mg, and 14 mg doses, Rybelsus produces meaningful glycemic control and modest weight loss at the 14 mg dose — approximately 4-5 kg in the PIONEER trials — making it inferior to injectable semaglutide for weight management purposes. However, in October 2025, the FDA approved Rybelsus for an expanded indication: cardiovascular risk reduction in adults with type 2 diabetes and established or high cardiovascular risk, based on the SOUL trial (n=9,650), which demonstrated a 14% relative reduction in major adverse cardiovascular events versus placebo over 4 years. This added the critical CV indication that transforms Rybelsus from a glycemic drug into a comprehensive metabolic risk-reduction tool for T2D patients who prefer oral therapy. Rybelsus occupies an important niche: it is the only oral GLP-1 approved for both glycemic control and cardiovascular risk reduction in type 2 diabetes. Monthly list price is approximately $900-$1,000 without insurance, though diabetes coverage in commercial and Medicare plans is generally more robust than for weight-loss-specific GLP-1s. The arrival of oral Wegovy (25 mg) and Foundayo has made Rybelsus less prominent in the weight-loss conversation, but it remains the definitive oral GLP-1 for T2D with established CV disease.

Saxenda (liraglutide 3 mg) holds a pivotal historical place in the GLP-1 weight-loss story: approved by the FDA in December 2014, it was the first GLP-1 receptor agonist approved specifically for chronic weight management — the drug that proved the class could produce clinically meaningful weight loss in adults without diabetes and transformed the regulatory and commercial calculus for all the agents that followed. Liraglutide is a once-daily subcutaneous injection that mimics the structure of natural GLP-1 with approximately 97% amino acid sequence identity to the human hormone, providing an 18-24 hour half-life that supports daily dosing. In the pivotal SCALE trials, Saxenda produced an average of 8-10% body weight reduction over 56 weeks in adults with obesity or overweight — lower than semaglutide and tirzepatide but representing a meaningful improvement over earlier pharmacotherapy options like orlistat (which averaged 3-5%). Clinical trial participants achieved a 5.8 kg weight loss versus 1.6 kg with placebo in the landmark SCALE Obesity and Prediabetes trial. Saxenda is also approved for adolescents aged 12-17 with obesity — a distinction no other weight-loss GLP-1 holds — making it uniquely positioned for pediatric obesity management. The single most important development for Saxenda in 2025-2026 is the FDA approval of a generic liraglutide injection for weight loss, announced in August 2025. Generic liraglutide costs $230-$500 per month — compared to Saxenda's $1,349 list price — and Teva's manufacturer savings program brings the cost to as low as $20 per prescription for commercially insured patients. This generic approval fundamentally changes the economics of liraglutide-based treatment, offering the GLP-1 class's safest and most established long-term safety profile at a dramatically lower price point. The once-daily injection requirement and lower efficacy than newer agents are its primary limitations, but for patients who cannot access semaglutide or tirzepatide due to cost or supply, generic liraglutide represents a viable and increasingly affordable bridge.

Wegovy is Novo Nordisk's brand name for semaglutide 2.4 mg delivered as a once-weekly subcutaneous injection, approved by the FDA in June 2021 for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. It is a pure GLP-1 receptor agonist — semaglutide binds to and activates the GLP-1 receptor with very high potency and, critically, has a long half-life of approximately one week, allowing for once-weekly dosing. The higher 2.4 mg dose used in Wegovy (versus the 1 mg or 2 mg doses in Ozempic) was specifically engineered to maximize weight-loss efficacy. The STEP 1 Phase 3 trial in adults without diabetes demonstrated average weight loss of 14.9% at 68 weeks — roughly 34 pounds — versus 2.4% for placebo. Among completers who adhered to treatment, average weight loss approached 16-17%. Importantly, Wegovy has a landmark cardiovascular outcomes dataset that no other pure weight-loss drug can match: the SELECT trial enrolled 17,604 non-diabetic adults with obesity or overweight and established cardiovascular disease (CVD), and demonstrated a 20% relative risk reduction in major adverse cardiovascular events (MACE) — heart attack, stroke, or cardiovascular death — over an average of 34 months. This led to FDA approval of a cardiovascular risk-reduction indication in March 2024, making Wegovy the first weight-loss drug ever approved to protect the heart. Weekly doses escalate from 0.25 mg through 0.5, 1.0, 1.7, and ultimately 2.4 mg over 16-20 weeks to minimize gastrointestinal side effects. Wegovy is delivered via a pre-filled, single-use autoinjector pen. The drug faces supply constraints that have historically limited access, though manufacturing expansion has improved availability. Monthly list price is approximately $1,349, with Novo Nordisk's savings program bringing costs to as low as $25 per month for eligible commercially insured patients.

Retatrutide is Eli Lilly's investigational triple receptor agonist, simultaneously activating GLP-1, GIP, and glucagon receptors — a pharmacological combination with no approved precedent. By adding glucagon receptor agonism to the dual GIP/GLP-1 profile of tirzepatide, retatrutide targets a third metabolic axis: energy expenditure. Glucagon receptor activation increases thermogenesis and fat oxidation in the liver and adipose tissue, providing a mechanism for weight loss that goes beyond appetite suppression alone. The Phase 2 trial published in 2023 showed up to 24% weight loss at 48 weeks in adults without diabetes at the 12 mg weekly dose — results that electrified the obesity medicine field. Then the Phase 3 program delivered results that were even more remarkable. TRIUMPH-4, reported in December 2025, showed a mean body-weight reduction of 28.7% at 68 weeks in the 12 mg group. Most strikingly, TRIUMPH-1, the pivotal obesity trial with its topline data announced in May 2026, reported up to 30.3% average weight loss at the highest dose — the single greatest weight-loss result ever recorded in a randomized Phase 3 clinical trial. At 12 mg over 96 weeks, participants had lost an average of approximately 70-71 pounds. Additional TRIUMPH-4 findings included a 75.8% reduction in osteoarthritis pain scores, approximately 20% reduction in LDL cholesterol, and a 72% reversal rate of prediabetes to normoglycemia. An NDA filing with the FDA is anticipated in late 2026, with approval expected in late 2027. Seven additional Phase 3 trials are reporting throughout 2026 across obesity subtypes, type 2 diabetes, and cardiovascular disease. Retatrutide does not yet have a commercial brand name, a list price, or an approved indication — but given the Phase 3 data, it represents the most anticipated drug in obesity medicine since Wegovy's 2021 approval.

CagriSema is Novo Nordisk's investigational fixed-dose combination of cagrilintide 2.4 mg (a long-acting amylin analogue) and semaglutide 2.4 mg, delivered as a single once-weekly subcutaneous injection. It represents a novel dual-hormone approach to weight management that goes beyond the GLP-1 receptor alone by adding amylin receptor activation. Amylin is a peptide hormone co-secreted with insulin from pancreatic beta cells, and it plays complementary roles in appetite suppression: it slows gastric emptying, suppresses glucagon secretion, and produces satiety signals via the central nervous system, particularly the area postrema and hypothalamus — pathways that are partially distinct from GLP-1 signaling. The hypothesis underlying CagriSema is that dual-pathway engagement produces additive or synergistic weight loss beyond what semaglutide achieves alone. The REDEFINE 1 Phase 3 trial in adults with obesity or overweight (without type 2 diabetes) reported impressive results: among participants evaluated for the treatment effect if all patients stayed on treatment, average weight loss was 22.7% at approximately 68 weeks. The full population analysis showed 20% average weight loss. Crucially, 91.9% of CagriSema-treated participants achieved at least 5% weight reduction, compared to 31.5% with placebo. Approximately one-third of participants reached 25% or greater weight loss, approaching surgical outcomes. Novo Nordisk submitted an NDA to the FDA on December 18, 2025, making CagriSema the most advanced next-generation obesity drug in the regulatory pipeline. The FDA is expected to complete its review in 2026, with a potential approval decision by late 2026 or early 2027. CagriSema is not yet approved in the US or EU. If approved, it would be the first amylin-class drug approved for obesity, representing a new mechanistic pillar in the field.

The oral Wegovy pill — formally oral semaglutide 25 mg — represents one of the most significant pharmaceutical advances in obesity medicine in years: it delivers the same active molecule as the injectable Wegovy in a once-daily tablet, eliminating the barrier of self-injection for patients who fear needles or prefer pill-based therapy. Approved by the FDA on December 22, 2025, and commercially available from January 2026, it is the first oral GLP-1 receptor agonist approved specifically for weight management in adults with obesity or overweight with at least one comorbidity. The OASIS 4 Phase 3 trial demonstrated that oral semaglutide 25 mg, taken once daily alongside a reduced-calorie diet and increased physical activity, produced an average weight loss of 16.6% among adherent participants — essentially matching the efficacy of injectable Wegovy in those who remained on treatment. The full population analysis (including those who discontinued) showed approximately 14% average weight loss. One-third of adherent participants achieved 20% or greater weight loss, compared to under 3% with placebo. Oral semaglutide does have one notable compliance requirement: the tablet must be taken on an empty stomach (fasting for at least 6 hours), with no more than 120 mL (4 oz) of plain water, and no food or drink for at least 30 minutes after ingestion. This is because GLP-1 peptides are poorly absorbed when co-ingested with food, and the tablet uses a proprietary absorption enhancer (SNAC — sodium N-[8-(2-hydroxybenzoyl)aminocaprylate]) to protect semaglutide from gastric digestion. This dosing protocol is stricter than the competitor oral GLP-1, Foundayo (orforglipron), which can be taken at any time without food restrictions — a practical distinction worth noting for patients with busy morning routines. List price is set at approximately $499 per month, with Novo Nordisk expected to offer savings programs. The oral formulation also carries the cardiovascular risk-reduction indication in adults with established CVD that was approved alongside the weight-loss NDA.

Foundayo (orforglipron) is Eli Lilly's FDA-approved once-daily oral GLP-1 receptor agonist approved on April 1, 2026 — a landmark drug for a specific reason beyond its efficacy. Unlike the oral semaglutide pill (Wegovy oral, Rybelsus), orforglipron is a small-molecule, non-peptide GLP-1 receptor agonist. This chemical class distinction has a critical practical consequence: because it is not a peptide, it does not get degraded by digestive enzymes in the way that semaglutide does, and it does not require a complex absorption enhancer. As a result, Foundayo can be taken at any time of day, with or without food, and without water restrictions — a unique advantage over all other oral GLP-1 drugs currently approved. The Phase 3 ATTAIN clinical trial program evaluated orforglipron across multiple doses and populations. At the highest dose (36 mg once daily) over 72 weeks, participants achieved an average weight loss of 12.4% — approximately 27 pounds — with an estimated 60% of participants achieving at least 10% body weight reduction. While 12.4% is lower than the 16.6% achieved with oral semaglutide in OASIS 4, the no-food-restriction dosing protocol may make adherence meaningfully better in real-world settings, particularly for patients with demanding work schedules or irregular meal patterns. Orforglipron launched commercially on April 6, 2026, via LillyDirect, followed by broader pharmacy and telehealth distribution. Critically, Lilly priced it at $149 per month for self-pay patients — dramatically below every other GLP-1 on the market. Some commercially insured patients pay as little as $25 per month with Lilly's savings card. This pricing strategy represents a deliberate effort to expand GLP-1 access well beyond the well-insured populations that have predominantly used Wegovy and Zepbound. Orforglipron does not yet carry a cardiovascular indication; outcomes trials are underway.

Ozempic contains the same molecule as Wegovy — semaglutide — but is FDA-approved primarily for glycemic control in type 2 diabetes at doses up to 2 mg weekly, and has accumulated the most expansive indication label of any GLP-1 receptor agonist on the market. Approved initially in December 2017, Ozempic now holds three distinct FDA-approved indications: (1) glycemic control in adults with type 2 diabetes; (2) reduction of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease (based on the SUSTAIN-6 and SELECT-adjacent data); and (3) — its most recent and clinically significant expansion, approved January 28, 2025 — reduction of the risk of worsening kidney disease, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease (CKD), based on the Phase 3b FLOW trial. The FLOW kidney outcomes trial is one of the most consequential studies in nephrology in decades. It demonstrated a 24% relative risk reduction in the composite of kidney disease worsening, end-stage kidney disease, and cardiovascular death with semaglutide versus placebo in a high-risk population with CKD (eGFR 25-75 mL/min/1.73m2). Additionally, it showed a 29% relative risk reduction in cardiovascular death — establishing semaglutide as the only GLP-1 RA approved to protect kidneys. While Ozempic is not formally approved for weight management (that indication sits with Wegovy at 2.4 mg), its use produces meaningful weight reduction as a beneficial secondary effect — typically 5-10% at the 1-2 mg doses — and it is one of the most commonly prescribed GLP-1s globally. Monthly list price is approximately $900-$1,000 without insurance; diabetes indications give it better insurance coverage than Wegovy in many plans. As the diabetes-labeled version of semaglutide, Ozempic serves as the entry point into the semaglutide family for millions of patients globally.

MariTide (maridebart cafraglutide) is Amgen's investigational antibody-peptide conjugate for obesity that targets the GLP-1 receptor as an agonist while simultaneously antagonizing the GIP receptor — a mechanistic approach that is the inverse of tirzepatide, which agonizes both GIP and GLP-1. The rationale is that blocking GIP signaling, rather than activating it, may reduce the energy-storing properties of GIP in adipose tissue while still benefiting from GLP-1-mediated appetite suppression. This hypothesis is pharmacologically contested — tirzepatide's GIP agonism clearly works — but MariTide's Phase 2 data demonstrate that GIP antagonism combined with GLP-1 agonism also produces meaningful weight loss. The Phase 2 trial results, published in the New England Journal of Medicine and presented at the American Diabetes Association's 85th Scientific Sessions, showed up to approximately 20% weight loss in non-diabetic adults with obesity after 52 weeks. Among participants with type 2 diabetes, weight loss reached approximately 17%, with HbA1c reductions of up to 1.6 percentage points and a high percentage achieving normoglycemia. Crucially, MariTide also demonstrated sustained weight loss for up to 52 weeks after the treatment period ended in some dose groups — a potential durability advantage over peptide-based GLP-1s, whose effects wane quickly after discontinuation. MariTide's most structurally distinctive feature is its dosing frequency: it is being developed as a once-monthly injection, and potentially even a once-quarterly formulation in the longer term, versus weekly injections for all current GLP-1s. This represents a paradigm-shifting convenience advantage if confirmed in Phase 3. However, Phase 2 results disappointed Wall Street relative to pre-release expectations (as reported by BioPharma Dive), and Phase 3 data will be decisive. Phase 3 studies are underway and will read out over 2026-2027.

Rybelsus is Novo Nordisk's once-daily oral semaglutide tablet approved in September 2019 for glycemic control in adults with type 2 diabetes. It was the world's first oral GLP-1 receptor agonist — a significant pharmaceutical achievement, given that GLP-1 peptides are ordinarily destroyed by gastric acid and proteases when taken by mouth. Rybelsus uses the proprietary SNAC (sodium N-[8-(2-hydroxybenzoyl)aminocaprylate]) absorption enhancer technology, which transiently raises local gastric pH and facilitates semaglutide absorption across the gastric mucosa. The mechanism requires strict fasting conditions: Rybelsus must be taken on an empty stomach with no more than 120 mL of plain water, with no food, drink, or other medications for at least 30 minutes afterward. Available in 3 mg, 7 mg, and 14 mg doses, Rybelsus produces meaningful glycemic control and modest weight loss at the 14 mg dose — approximately 4-5 kg in the PIONEER trials — making it inferior to injectable semaglutide for weight management purposes. However, in October 2025, the FDA approved Rybelsus for an expanded indication: cardiovascular risk reduction in adults with type 2 diabetes and established or high cardiovascular risk, based on the SOUL trial (n=9,650), which demonstrated a 14% relative reduction in major adverse cardiovascular events versus placebo over 4 years. This added the critical CV indication that transforms Rybelsus from a glycemic drug into a comprehensive metabolic risk-reduction tool for T2D patients who prefer oral therapy. Rybelsus occupies an important niche: it is the only oral GLP-1 approved for both glycemic control and cardiovascular risk reduction in type 2 diabetes. Monthly list price is approximately $900-$1,000 without insurance, though diabetes coverage in commercial and Medicare plans is generally more robust than for weight-loss-specific GLP-1s. The arrival of oral Wegovy (25 mg) and Foundayo has made Rybelsus less prominent in the weight-loss conversation, but it remains the definitive oral GLP-1 for T2D with established CV disease.

Saxenda (liraglutide 3 mg) holds a pivotal historical place in the GLP-1 weight-loss story: approved by the FDA in December 2014, it was the first GLP-1 receptor agonist approved specifically for chronic weight management — the drug that proved the class could produce clinically meaningful weight loss in adults without diabetes and transformed the regulatory and commercial calculus for all the agents that followed. Liraglutide is a once-daily subcutaneous injection that mimics the structure of natural GLP-1 with approximately 97% amino acid sequence identity to the human hormone, providing an 18-24 hour half-life that supports daily dosing. In the pivotal SCALE trials, Saxenda produced an average of 8-10% body weight reduction over 56 weeks in adults with obesity or overweight — lower than semaglutide and tirzepatide but representing a meaningful improvement over earlier pharmacotherapy options like orlistat (which averaged 3-5%). Clinical trial participants achieved a 5.8 kg weight loss versus 1.6 kg with placebo in the landmark SCALE Obesity and Prediabetes trial. Saxenda is also approved for adolescents aged 12-17 with obesity — a distinction no other weight-loss GLP-1 holds — making it uniquely positioned for pediatric obesity management. The single most important development for Saxenda in 2025-2026 is the FDA approval of a generic liraglutide injection for weight loss, announced in August 2025. Generic liraglutide costs $230-$500 per month — compared to Saxenda's $1,349 list price — and Teva's manufacturer savings program brings the cost to as low as $20 per prescription for commercially insured patients. This generic approval fundamentally changes the economics of liraglutide-based treatment, offering the GLP-1 class's safest and most established long-term safety profile at a dramatically lower price point. The once-daily injection requirement and lower efficacy than newer agents are its primary limitations, but for patients who cannot access semaglutide or tirzepatide due to cost or supply, generic liraglutide represents a viable and increasingly affordable bridge.